|
2020 Conference Publication Human CD141+dendritic cells (cDC1) are impaired in advanced melanoma patients but can be targeted to increase efficacy of anti-PD-1 checkpoint inhibitor therapyO'Brien, Liam, Lee, Yoke Seng, Walpole, Carina, Rojas, Ingrid Leal, Masterman, Kelly-Anne, Atkinson, Victoria, Barbour, Andrew and Radford, Kristen (2020). Human CD141+dendritic cells (cDC1) are impaired in advanced melanoma patients but can be targeted to increase efficacy of anti-PD-1 checkpoint inhibitor therapy. AACR Special Conference on Tumor Immunology and Immunotherapy, Boston, MA, United States, 17-20 November, 2019. Philadelphia, PA, United States: American Association for Cancer Research. |
